Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 122

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 122
---
 Stockholders, and
(b) recommended that the Enfusion Board adopt resolutions declaring that the Merger Agreement, the Mergers and the other transactions contemplated by the Merger Agreement are advisable, fair to and in the best interests of Enfusion and Enfusion
Stockholders, adopt and approve the Merger Agreement, the Mergers and the other transactions contemplated by the Merger Agreement, and recommend that the Enfusion Stockholders vote their shares in favor of adopting the Merger Agreement at a special
meeting of the Enfusion Stockholders (the “”).

Immediately following such Special Committee
meeting on January 10, 2025, the Enfusion Board held a meeting with representatives of Dechert, Goldman Sachs and Goodwin in attendance. Representatives of Goldman Sachs reviewed with the Enfusion Board its financial analysis of the
proposed Merger Consideration. Representatives of Dechert reviewed the final terms of the merger agreement, the voting and support agreements and the TRA amendment. Representatives of Goodwin then reviewed with the Enfusion Board its fiduciary
duties under Delaware law. Members of the Special Committee and representatives of Dechert described and conveyed the Special Committee Resolutions to the Enfusion Board. The Enfusion Board then unanimously (a) determined that the Merger
Agreement, the Mergers and the other transactions contemplated by the Merger Agreement were advisable, fair to and in the best interests of Enfusion and Enfusion Stockholders, (b) adopted and approved the Merger Agreement, the Mergers and the
other transactions contemplated by the Merger Agreement and (c) directed that the Merger Agreement be submitted to Enfusion Stockholders entitled to vote thereon for adoption thereby and resolved to recommend that Enfusion Stockholders adopt
the Merger Agreement and approve the transactions contemplated by the Merger Agreement, including the Mergers.

77

Later on January 10, 2025, the TRA amendment, the merger agreement and the voting and support agreements were executed by the relevant parties. On January 13, 2025, before the opening of trading on the NYSE, Enfusion and Clearwater publicly announced the merger. Enfusion’s Reasons for the Transactions; Recommendations of the Special Committee and the Enfusion Board Recommendations of the Special Committee The Special Committee, pursuant to resolutions adopted at a meeting of the Special Committee held on January 10, 2025, unanimously (i) determined that the Merger Agreement, the Merger and the other Transactions are advisable